What is exciting is the extensive variety of joints patients have successfully used FLEXISEQ to treat.

Munich, Germany (PRWEB UK) 29 March 2013

Pro Bono Bio welcomes the results from an independent patient survey of its product, Flexiseq conducted by the German product-testing community, The survey was performed among the community’s osteoarthritis members capturing their “real-life” experiences of the product and producing results that complement Flexiseq's impressive clinical data.

FLEXISEQ® Wins BVDA Innovation of 2013 Award

Published in News

Innovative New Treatment for the Symptoms of Osteoarthritis

Frankfurt/London 24th January 2013 – The Federal Association of German Pharmacists (BVDA) today presented its “Innovation Award 2013” to FLEXISEQ®, an innovative new treatment for pain and stiffness associated with osteoarthritis (OA).

Michael Earl receiving BVDA Award for FLEXISEQ

FLEXISEQ™ for Hajj Pilgrims

Published in News

Pro Bono Bio™ Humanitarian Donation Dakar/London 11th June 2012

FLEXISEQ for Hajj PilgrimsPro Bono Bio is pleased to announce that its Humanitarian Division has made its first charitable donation of products following its commitment to help healthcare in Africa. The donation was made by Pro Bono Bio’s envoy Andrei Garbuz (pictured) to thehead of commission for pilgrimage to holy places of Islam, Mr El Hadji Mansour DIOP in Dakar. The Commissioner General commented "It is with great pleasure and genuine interest that I received the consignment of FLEXISEQ products, kindly made available to the Senegalese pilgrims for the 2012 Hajj. Experience gained from the previous Hajjes shows the point to which osteoarthritis affects the majority of our elderly pilgrims and is the subject of regular consultations with our medical team. This shows the great interest which our pilgrims, and we ourselves, have in such a gesture. Allow me, on behalf of all Senegalese pilgrims and the government of Senegal, to send you our sincere thanks."

Malaysian Approval of FLEXISEQ™ and distribution agreement

Published in News

New Osteoarthritis treatment for Malaysia

Kuala Lumpur/London 15th June 2012 - Pro Bono Bio™ is pleased to announce that its innovative product FLEXISEQ, a new nanotechnology based treatment for osteoarthritis, has received approval for sale in Malaysia. This follows the successful launch of FLEXISEQ in Europe earlier this year.

Pro Bono Bio is also pleased to announce that they have signed an agreement to distribute FLEXISEQ in Malaysia and the product will be available via local distribution company, Farmasia Sdn. Bhd. from early July 2012. Its first introduction to the local market is at the 42nd Annual Scientific Meeting of the Malaysian Orthopaedic Association in Kuantan, Malayisa held between the 14th and 17th of June 2012.

Page 2 of 2